Novo Nordisk (NVO) is on pace to gap lower at the opening bell today, with shares of the pharma giant plunging up to 30% in premarket trading following its second forecast cut of 2025. The Danish drug company drastically reduced its full-year sales growth guidance to 8-14% from 13-21%, while operating profit growth expectations were lowered to 10-16% from 16-24%.
